title: Targeting blood vessels for the treatment of non-small cell lung cancer.
abstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Although modest survival benefit has been observed with surgery, radiotherapy and platinum-based chemotherapy, an efficacy plateau has been reached. It has become obvious, therefore, that additional treatments are needed in order to provide an improved survival benefit for these patients. The use of molecular targeted therapies, particularly those against tumor capillaries, has the potential to improve outcomes for NSCLC patients. Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is the first targeted drug that has shown survival advantage when combined with chemotherapy in NSCLC. Other antivascular agents, including vascular disrupting agents (VDAs) and different small-molecule receptor tyrosine kinase inhibitors, have also shown promise in phase I and II trials in NSCLC. The aim of this study is to describe the clinical properties of these drugs and to discuss the evidence that supports their use in the treatment of NSCLC. Furthermore, we plan to review the main pitfalls of antivascular strategies in NSCLC cancer therapy as well as assess the future direction of these treatment methods with an emphasis on clarifying the molecular background of the effects of these drugs and defining the biomarkers.
authors.affiliation: Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.
authors.forename: Ethan
authors.initials: E
authors.lastname: Amir
authors.forename: Sarah
authors.initials: S
authors.lastname: Hughes
authors.forename: Fiona
authors.initials: F
authors.lastname: Blackhall
authors.forename: Nick
authors.initials: N
authors.lastname: Thatcher
authors.forename: Gyula
authors.initials: G
authors.lastname: Ostoros
authors.forename: Jozsef
authors.initials: J
authors.lastname: Timar
authors.forename: Jozsef
authors.initials: J
authors.lastname: Tovari
authors.forename: Gabor
authors.initials: G
authors.lastname: Kovacs
authors.forename: Balazs
authors.initials: B
authors.lastname: Dome
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A